ArticleJAMA dermatology2017
Pediatric Psoriasis Comorbidity Screening Guidelines.
Article in JAMA dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 106 citations in OpenAlex.
- Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.Paediatric drugs · 2025Trial
- Efficacy of Motivational Interviewing to Improve Utilization of Mental Health Services Among Youths With Chronic Medical Conditions: A Cluster Randomized Clinical Trial.JAMA network open · 2021Trial
- Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs.Dermatology and therapy · 2026Review
- Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis.Journal of psoriasis and psoriatic arthritis · 2026Article
- Pediatric psoriasis: A descriptive, retrospective and multicenter study in ColombiaBiomedica : revista del Instituto Nacional de Salud · 2025Article
- The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Psoriasis in the paediatric population: assessment of comorbidities, risk factors of their occurrence, quality of life of patients and therapy implemented.Postepy dermatologii i alergologii · 2025Article
- [Inflammatory dermatoses in children and adolescents : Diagnosis and treatment of atopic dermatitis and psoriasis].Dermatologie (Heidelberg, Germany) · 2024Review
- The Saudi consensus recommendations for the management of psoriatic arthritis (2023).Clinical rheumatology · 2024Review
- Article
- [Recommendations for individual comorbidity risk assessment in adult patients with psoriasis].Dermatologie (Heidelberg, Germany) · 2023Review
- Psoriasis and Cardiovascular Risk in Children: The Usefulness of Carotid Intima-Media Thickness.Pediatric cardiology · 2022Article
- Update on the Management of Pediatric Psoriasis: An Italian Consensus.Dermatology and therapy · 2022Article
- Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review.Healthcare (Basel, Switzerland) · 2022Article
- Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses.Frontiers in medicine · 2022Article
- Associations of muscle-strengthening exercise with overweight, obesity, and depressive symptoms in adolescents: Findings from 2019 Youth Risk Behavior Surveillance system.Frontiers in psychology · 2022Article
- Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management.Psoriasis (Auckland, N.Z.) · 2022Review
- Recommendations for Management of Childhood Psoriasis.Indian dermatology online journal · 2021Article
- Review
- Screening for Comorbid Cardiovascular Risk Factors in Pediatric Psoriasis Among Iraqi Patients: A Case-Control Study.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 15 institutions in 1 country.
Funding
Abstract
Importance: Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. Objective: To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. Evidence Review: A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence. Findings: Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs and symptoms of arthritis, depression, and anxiety. The panel also identified key areas for further investigation. Conclusions and Relevance: Patients with pediatric psoriasis should receive routine screening and identification of risk factors for associated comorbidities. These guidelines are relevant for all health care providers caring for patients with pediatric psoriasis, including primary care clinicians, dermatologists, and pediatric specialists. Because these are the first pediatric guidelines, re-review and refinement will be necessary as studies further detail, and possibly stratify, risk in affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.